He said it was pummeled because it missed earnings, but I'm not sure how many people trade development stage biotechs based on "earnings." I think it was the resounding silence on a milestone payment from PG for moving PTH into clinical trials that left a hole in revenues, plus the fact that they increased spending on research and trials which don't have outsidde funding that hurt. So, okay, maybe this counts as an "earnings" miss..
Market Data 
Markets 
AI
